WebMay 26, 2024 · The AGILE trial is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the efficacy and safety of TIBSOVO in combination with azacitidine compared with placebo in combination with azacitidine, in adults with previously untreated IDH1-mutated acute myeloid leukemia (AML) who are … WebDec 23, 2024 · Dec 23, 2024 Pau Montesinos, MD, PhD, discusses the AGILE phase 3 clinical trial for newly diagnosed patients with acute myeloid leukemia with an IDH1 …
ASH: Servier
WebMay 25, 2024 · The AGILE trial is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the efficacy and safety of TIBSOVO … WebJun 16, 2024 · The AGILE trial showed a clear advantage with a median overall survival of over 24 months and markedly enhanced outcomes on every parameter looked at, favoring the ivosidenib and azacitidine. buffalo wearing shorts
Phase 3 AGILE Data of TIBSOVO® (ivosidenib ... - servier.us
WebJun 4, 2024 · Significant clinical benefit has been shown with ivosidenib (Tibsovo), a potent oral targeted inhibitor of IDH1, plus azacitidine (AZA; Vidaza) vs placebo plus azacitidine in patients with newly-diagnosed IDH1-mutant acute myeloid leukemia (AML), according to findingd from the phase 3 AGILE trial (NCT03173248). 1. Results from AGILE supported … WebApr 28, 2024 · In the phase 3 QUAZAR AML-001 trial (NCT01757535), patients at least 55 years of age with AML and intermediate- or poor-risk cytogenetics who achieved a complete response (CR) or CR with... WebNov 23, 2024 · AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute … buffalo weather cam live